[Combination chemotherapy of CPM-MTX-5-FU in non-resectable and recurrent cancer patients].
Toshiaki Saeki(Saitama International Medical Center), T. Hattori(Hiroshima University), K Yoshinaka(Hiroshima University), K Jinushi(Hiroshima University), E Yanagawa(Hiroshima University), Minoru Niimoto(Hiroshima University), Masakazu Toi(Mukogawa Women's University), Kyosuke Saeki(Ehime Prefectural Central Hospital), R. Kim(Hiroshima University)
PubMed
April 1, 1989
Cited by 0
Related Papers
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
|Journal of Clinical Oncology|2017|1.7k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|1k
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830